Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Parallel Group, Phase 2 to Establish the Efficacy and Safety of Combinations of CBP501, Cisplatin, and Nivolumab for ≥3rd Line Treatment of Patients With Exocrine Pancreatic Cancer and WBC <10,000/mm3 at Screening

NCT04953962 is registered in ClinicalTrials.gov with CanBas Co. Ltd. as lead sponsor.

NCT NCT04953962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04953962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Parallel Group, Phase 2 to Establish the Efficacy and Safety of Combinations of CBP501, Cisplatin, and Nivolumab for ≥3rd Line Treatment of Patients With Exocrine Pancreatic Cancer and WBC <10,000/mm3 at Screening
Lead sponsor
CanBas Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2021
Completion date
April 14, 2023
Enrollment
36 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer stage iv